Wehling, Martin
Petrovic, Mirko
Funding for this research was provided by:
Medizinische Fakultät Mannheim der Universität Heidelberg
Article History
First Online: 5 November 2021
Conflicts of interest
: MW was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Sanofi-Aventis, Bayer, Berlin-Chemie, Boehringer Ingelheim, Aspen, Novartis, Takeda, Roche, Pfizer, Heel, Bristol-Myers, Daichii-Sankyo, Santhera, Lilly, Otsuka, Novo-Nordisk, Shire and LEO Pharma. MP has no conflicts of interest to declare.
: Not applicable, no study.
: Not applicable, no study.